Pharma BD Deal Intelligence
Agilent Technologies' acquisition of Resolution Bioscience for up to $695 million delivered on the diagnostics thesis: the platform produced Agilent's first FDA-approved liquid-biopsy companion diagnostic, the Resolution ctDx FIRST test for KRAS G12C-mutated NSCLC, approved December 2022 and expanded via a Quest Diagnostics access partnership in January 2023.
Agilent Technologies acquired Resolution Bioscience for $550 million in cash at closing plus up to $145 million in performance milestones (total up to $695 million), expanding Agilent's capabilities in NGS-based liquid biopsy cancer diagnostics and precision medicine. Post-close, the acquired platform delivered Agilent's first FDA-approved liquid-biopsy companion diagnostic: the Agilent Resolution ctDx FIRST (PMA P210040) won FDA approval on December 12, 2022 as the first liquid-biopsy CDx to identify KRAS G12C-mutated advanced NSCLC patients eligible for Krazati (adagrasib, Mirati Therapeutics), and in January 2023 Agilent partnered with Quest Diagnostics to extend US national access to the test.
Agilent Technologies acquired Resolution Bioscience for $550 million in cash at closing plus up to $145 million in performance milestones (total up to $695 million), expanding Agilent's capabilities in NGS-based liquid biopsy cancer diagnostics and precision medicine.
The Resolution Bioscience NGS liquid-biopsy platform Agilent acquired in 2021 won FDA premarket approval (PMA P210040) on December 12, 2022 as the first liquid-biopsy companion diagnostic to identify KRAS G12C-mutated advanced NSCLC patients eligible for Krazati (adagrasib, Mirati Therapeutics). Realizes the deal's CDx thesis.
Agilent announced a collaboration with Quest Diagnostics to make the FDA-approved Agilent Resolution ctDx FIRST liquid-biopsy test orderable nationwide via Quest's connectivity platform and ~2,100 US patient service centers, broadening commercial reach.
Significant transaction at $695M. Agilent Technologies acquired Resolution Bioscience for $550 million in cash at closing plus up to $145 million in performance milestones (total up to $695 million), expanding Agilent's capabilities i
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Agilent Technologies Inc. / Resolution Bioscience Inc. (this deal) | 2021 | $695M | 32 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2021 deals · Oncology deals